Biorce
Biorce sells Aika 2.0, an AI operating system for clinical development, to pharmaceutical and biotechnology sponsors and contract research organizations. Four modules are live. Protocol drafts the protocol, investigator's brochure and informed consent form; Simulation runs power, sample size and Monte Carlo scenarios; Feasibility scores sites, countries and patient pools; and Contracts & Budgets handles clinical trial agreement redlining, fair market value benchmarking and budgets. When a protocol changes, Aika carries the change into the connected simulations, feasibility work, costs and contracts and queues each update for the sponsor's team to approve, under the line "Aika proposes, your team decides." Proposal, Sites, Eligibility, Data and Oversight are still in development.
Aika grounds its drafts in a clinical knowledge graph built on about 1 million clinical trial records and more than 390,000 protocols, and every number in a workspace links to its source. Biorce cites a top 15 pharmaceutical company whose oncology protocol design ran 75% faster, saving $400,000 per study, and puts protocol drafting at under 30 days against a 90 day baseline. Google and NVIDIA are named partners. Pedro Coelho founded the company in Barcelona in 2022. Its $52.5 million Series A in February 2026, led by DST Global Partners with Norrsken VC and YZR Capital, took total funding past $60 million, and it opened an Austin office later that year.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Generation is the product. Aika drafts the protocol, investigator's brochure and informed consent form, runs power and sample size simulations, scores sites and countries, and redlines clinical trial agreements and budgets, all from one set of study decisions. When someone changes the protocol, the model works out which simulations, feasibility estimates, cost projections and contract terms the change touches and proposes updates to each.
The knowledge graph and data foundation supply the context and the workspace stores versions, but the reason a sponsor buys is the drafting and the cascade. Without the model the workspace would be a document repository.
Aika proposes and the sponsor's team decides: a protocol change triggers proposed updates to connected simulations, feasibility work, budgets and contracts, and each waits for review and approval before it replaces the current version. Documents stay under the sponsor's control, and the privacy notice adds that Biorce does not use data for automated decision making without human oversight. On the release side, Biorce's scientific team holds approval authority over new features.
What the system does when sources conflict, when a cascade cannot resolve an inconsistency, or when a document should be held back from export is not described, so review has no stated trigger beyond every change.
Aika's intelligence layer sits on a data foundation and a clinical knowledge graph that harmonizes scientific and regulatory information, built on about 1 million clinical trial records and more than 390,000 protocols. Protocol changes carry context into simulations and operational documents, numerical outputs link to their sources, and the scientific team sets acceptance criteria and tests features before they go live. Google and NVIDIA are named as partners.
Which foundation models generate the drafts, whether Biorce trains or adapts its own, what data trained them and how a new model version is announced to a sponsor in the middle of a study are not stated.
Google Cloud Platform is the one infrastructure provider on Biorce's subprocessor list, and service providers work under data processing agreements, with EU standard contractual clauses covering transfers outside Europe. Google and NVIDIA appear as partners.
The model layer is the gap: no provider is named for the language models that draft protocols and contracts, and nothing says whether sponsor documents reach an outside model service for inference, or on what retention and training terms. Naming the host leaves open the question that matters most to a sponsor, which is who else handles an unpublished protocol.
The product result is an unnamed top 15 pharmaceutical company's oncology program, where protocol design ran 75% faster and saved $400,000 per study; the product page puts the same $400,000 against each amendment instead. Neither figure comes with a sample, period, baseline or method.
The homepage adds a 60% cost reduction, a 70% faster development workflow and 50% fewer protocol amendments, without baselines, and at the Series A Clinical Trials Arena reported regulator ready protocols in 90 seconds at 86% accuracy, again with no method behind it. No customer is named against any result, and no study compares amendment rates or enrollment with and without Aika.
Sponsors bring their own documents and data into the workspace, where Aika combines them with its knowledge graph, and each workspace is labeled a private tenant. The privacy notice, which covers website visitors, client contacts and suppliers rather than Aika, keeps account data until deletion plus 30 days, marketing data for three years and usage analytics for two years, anonymized after six months, and the trust center lists deletion of customer data when a customer leaves.
Retention for study documents and generated drafts, whether sponsor material trains Aika's models, how any patient level data is deidentified and how a safety event is handled are not set out for the application.
Biorce calls Aika HIPAA compliant on its product page, HIPAA ready elsewhere, and GDPR compliant. The privacy notice, issued by Biorce S.A., Biorce ESP SL and Biorce, Inc., covers website visitors, client contacts and suppliers and does not mention Aika, business associates or study data, and the terms for the application are not public.
Most sponsor material in protocol and feasibility work is not protected health information, but the Eligibility and Data modules in development point toward patient level records. No business associate status, agreement or tier is stated for the cases where one would apply, so the compliance claim stands without a document behind it.
Biorce holds a SOC 2 Type II attestation, shown with the AICPA badge on its site, and the trust center lists the SOC 2 Type II report and a penetration test, both released through an access request. Policies on cryptography, data management, incident response and third party management are available the same way, and the trust center shows selected controls for infrastructure, product security and data privacy, including deletion of customer data on departure. Aika is described as aligned with ISO/IEC 27001, a statement of alignment rather than a certificate. The report's period and the systems it covers are visible only once access is granted.
The live modules support decisions a sponsor makes about designing and running a trial: protocol content, sample size, country and site selection, contract terms and budgets. Aika can prepare regulatory documentation for qualified staff to review, and Biorce calls the platform GxP ready, FDA/EMA compliant and audit ready. Those phrases describe fitness for regulated research work rather than a device position, and no output is a patient specific diagnosis or treatment decision. Biorce makes no medical device claim and sells nothing that would need one, though no statement explains which regulations the GxP and audit ready claims refer to.
New features pass through Biorce's scientific team, which defines what a correct output looks like, tests against those acceptance criteria and holds authority to approve a release, with independent clinical experts evaluating outputs and assessment in real clinical settings before general use. Its clinical experts cover all therapeutic areas and help develop features, and each sponsor gets an assigned scientific partner during onboarding.
That is a named process with people accountable for it. No results show how protocol quality, simulation accuracy or feasibility estimates hold up across therapeutic areas, trial phases, rare disease populations or regions, and no outside audit of model behavior is named.
Every number in a workspace traces to its source, so when a protocol change moves a feasibility estimate or a budget line, a reviewer can see which assumption drove it and challenge it before approval. Updates arrive as proposals for the sponsor's team to accept, and the assigned scientific partner takes questions during live use. Biorce's case material calls the platform FDA/EMA compliant and audit ready.
No warranty, correction commitment or credit attaches to a flawed protocol section, a wrong sample size or a mispriced budget, and the terms governing the application are not public, so responsibility for an error sits with the sponsor's reviewers.
Trial planning has no clinical record surface, and Aika connects to none. Its integrations layer instead links a sponsor's existing enterprise systems and proprietary data, and its regulatory documents are produced eTMF ready. No clinical trial management system, electronic trial master file, electronic data capture platform or sponsor data warehouse is named as a live connection, and the Data module, which covers data management and trial integration, is still in development. For now the exchange runs through documents moving in and out of the workspace rather than through a named system that receives protocol changes automatically.
Aika runs as a hosted application on Google Cloud Platform, the infrastructure provider on Biorce's subprocessor list, and each customer workspace is labeled a private tenant. Biorce operates through Biorce S.A. and Biorce ESP SL in Spain and Biorce, Inc. in the United States, with offices in Barcelona, Austin and New York, and the privacy notice relies on EU standard contractual clauses and adequacy decisions for transfers outside the UK and European Economic Area.
The Google Cloud region holding sponsor data, whether a sponsor can choose one, and where model processing happens are not stated, so residency is implied by the corporate footprint rather than committed.
Aika is sold through a demonstration, often a 30 minute walkthrough with oncology clinical experts or a session on a study resembling the buyer's own program, and existing customers sign in to a separate application. No price, license unit or term is shown for the platform or any module.
The economics Biorce leads with sit on the buyer's side of the ledger: protocols taking 90 days and amendments costing up to $535,000 each before Aika, against under 30 days and more than $100 million protected from Phase 1 to approval after. How sponsors are charged, whether per study, per seat, per module or by enterprise license, comes only in the sales conversation.
Buyers are pharmaceutical and biotechnology sponsors and contract research organizations, specifically their clinical operations, biostatistics and regulatory teams, from IND through approval. Feasibility covers site, country and patient pool choices, and Contracts & Budgets the activation paperwork. The one result is oncology protocol work at a top 15 pharmaceutical company, and Biorce runs demos with oncology clinical experts while saying its clinical experts cover all therapeutic areas. Rare disease, cell and gene therapy, device trials and early versus late phase work are not singled out, so coverage outside oncology protocols rests on that claim of breadth rather than on results.
Alternatives to Biorce
Other products that do the same kind of work as Biorce, and what each one does.
OPFOR Supply plans investigational product for clinical trials: how many kits to make, when to make them and which depot should hold them.
PhaseV provides clinical development software for pharmaceutical sponsors, biotechnology companies and contract research organizations, from offices in the Boston area and Tel Aviv, and says more than 40 biopharma companies and CROs use it.
ConcertAI's Accelerated Clinical Trials platform helps pharmaceutical sponsors and contract research organizations design, plan and run oncology studies.
Clinical trial platform that embeds patient identification, eSource and data capture inside provider organizations so trials can run in routine care, paired with its own recruitment coordinators and eligibility specialists.
QuantHealth is a clinical trial simulation company with offices in Tel Aviv and Worcester, Massachusetts.
AiCure's H.Code platform verifies how clinical trial participants take their medication between visits.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact sales
|
Aika 2.0 is sold through a demonstration on a study resembling the buyer's own program. No rate, license unit or term length is shown for the platform or its modules. | Aika is described as HIPAA compliant, but no business associate agreement, or the arrangements it would apply to, is stated. | Each sponsor gets an assigned scientific partner during onboarding. No separate implementation, data migration or integration fee is stated. | Vendor Published |
The four live modules cover protocol development, simulation, feasibility, and contracts and budgets. Pricing by module, study or seat, and any charge for connecting a sponsor's own data, come with the quote.